ERS 2026: Brensocatib cuts NCFB exacerbations in NTM history patients

Brensocatib was FDA approved in August 2025, marking the first approved therapy for NCFB. Brensocatib was FDA approved in August 2025, marking the first approved therapy for NCFB. The trial enrolled patients with patients with non-cystic fibrosis bronchiectasis (NCFB) with a history of nontuberculosis mycobacteria (NTM) infection. Credit: ART-ur/Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise. Hard data…

Source: Clinical Trials Arena